Last reviewed · How we verify
Papacarie
Papacarie is a Small molecule drug developed by Nourhan M.Aly. It is currently in Phase 2 development. Also known as: Papacarie-Duo.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Papacarie |
|---|---|
| Also known as | Papacarie-Duo |
| Sponsor | Nourhan M.Aly |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Chemo-mechanical Caries Removal Materials in Caries Removal (NA)
- Clinical Evaluation and Antimicrobial Effect of Papain Based Chemo-mechanical Caries Removal Agents (NA)
- Impact of Minimally Invasive Restorative Techniques on Pregnant Women Oral Health Related Quality of Life (PHASE2)
- Evaluation of Antimicrobial Photodynamic Therapy and Minimal Intervention Associated With Deproteinization in Permanent Teeth With Molar Incisor Hypomineralization (PHASE1, PHASE2)
- Antimicrobial Photodynamic Therapy as an Adjunct for Management of Deep Caries Lesions (PHASE2)
- The Impact of Minimally Invasive Restorative Techniques on Dental Pain in Pregnant Women (PHASE2)
- Discomfort Evaluation During Atraumatic Restorative Treatment in Children (NA)
- A Comparative Study of Papacarie® and the Conventional Method for Dental Caries Treatment (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Papacarie CI brief — competitive landscape report
- Papacarie updates RSS · CI watch RSS
- Nourhan M.Aly portfolio CI
Frequently asked questions about Papacarie
What is Papacarie?
Who makes Papacarie?
Is Papacarie also known as anything else?
What development phase is Papacarie in?
Related
- Manufacturer: Nourhan M.Aly — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Papacarie-Duo
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing